Skip to main content Accessibility help
Hostname: page-component-8bbf57454-kwtxg Total loading time: 0.393 Render date: 2022-01-25T05:06:45.870Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

38 - Management of cancer of the thyroid

Published online by Cambridge University Press:  05 November 2015

Laura Moss
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access


Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


ARSAC. (2006). ARSAC Notes for Guidance. Health Protection Agency for the Administration of Radioactive Substances Committee.
Barbet, J., Campion, L. and Kraeber-Bodéré, F. (2005). Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab., 90, 6077–6084.CrossRefGoogle ScholarPubMed
Bartalena, L., Marcocci, C., Bogazzi, F., et al. (1998). Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N. Engl. J. Med., 338, 73–78.CrossRefGoogle ScholarPubMed
Barwick, T. D., Dhawan, R. T. and Lewington, V. (2012). Role of SPECT CT in differentiated thyroid cancer. Nucl. Med. Commun., 33, 787–798.CrossRefGoogle ScholarPubMed
Cheng, W., Ma, C. and Fu, H. (2013). Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J. Clin. Endocrinol. Metab., 98, 1353–1360.CrossRefGoogle ScholarPubMed
De Groot, L., Abalovich, M., Alexander, E.K., et al. (2012). Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 97, 2543–2565.CrossRefGoogle Scholar
Mallick, U., Harmer, C., Yap, B., et al. (2012). Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med., 366, 1674–1685.CrossRefGoogle ScholarPubMed
McGriff, N. J., Csado, G., Gourgiotis, L., et al. (2002). Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med., 34, 554–564.CrossRefGoogle ScholarPubMed
O'Neill, C. J., Vaughan, L., Learoyd, D. L., et al. (2011). Management of follicular thyroid carcinoma should be individualized based on degree of capsular and vascular invasion. Eur. J. Surg. Oncol., 37, 181–185.Google Scholar
Perros, P., Colley, S., Boelaert, K., et al. (2014). British Thyroid Association guidelines for the management of thyroid cancer. Clin. Endocrinol., 81, Suppl. 1.CrossRefGoogle ScholarPubMed
Schlumberger, M., Bastholt, L., Dralle, H., et al. (2012). 2012 European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur. Thyroid J., 1, 5–14.CrossRefGoogle ScholarPubMed
Smallridge, R. C., Ain, K. B., Asa, S. L., et al. (2012). American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid, 22, 1104–1139.CrossRefGoogle ScholarPubMed
Stagnaro-Green, A., Abalovich, M., Alexander, E., et al. (2011). Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid, 21, 1081–1125.CrossRefGoogle ScholarPubMed
Sugino, K., Kameyama, K., Ito, K., et al. (2012). Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. Thyroid, 22, 798–804.CrossRefGoogle ScholarPubMed
Tuttle, R. M., Tala, H. and Shah, J. (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid, 20, 1341–1349.CrossRefGoogle ScholarPubMed
UICC (2009). In TNM Classification of Malignant Tumours (7th edition). Ed. Sobin, L. H., Gospodarowitc, M. K. and Wittekind, Ch.. Oxford: Wiley-Blackwell, pp. 58–62.
ATA Guidelines Taskforce. (2009). Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19, 565–612.
ATA Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167–1214.
Castagna, M. G., Mainom, F., Cipri, C., et al. (2011). Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol., 165, 441–446.CrossRefGoogle Scholar
Iyer, N. G., Morris, L. G., Tuttle, R. M., et al. (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 117, 4439–4446.CrossRefGoogle ScholarPubMed
Kim, K. B., Cabanillas, M. E., Lazar, A. J., et al. (2013). Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid, 23, 1277–1283.CrossRefGoogle ScholarPubMed
Mazzaferri, E., Robbins, R., Spencer, C., et al. (2003). A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 88, 1433–1441.Google ScholarPubMed
Nixon, I. J., Ganly, I., Patel, S. G., et al. (2013). The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid, 23, 683–694.CrossRefGoogle ScholarPubMed
Rubino, C., de Vathaire, F., Dottorini, M. E., et al. (2003). Second primary malignancies in thyroid cancer patients. Br. J. Cancer, 89, 1638–1644.CrossRefGoogle ScholarPubMed
Walsh, S., Lowery, A. J., Evoy, D., et al. (2013). Thyroid lymphoma: recent advances in diagnosis and optimal management strategies. The Oncologist, 18, 994–1003.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats